

The opinion in support of the decision being entered today was not written
for publication and is not binding precedent of the Board.


UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE BOARD OF PATENT APPEALS AND INTERFERENCES

Ex parte JOHN SEFTON

Appeal No. 2005-0938
Application No. 09/367,712

ON BRIEF



Before WILLIAM F. SMITH, ADAMS, and POTEATE, Administrative Patent Judges.

ADAMS, Administrative Patent Judge.

DECISION ON APPEAL

This is a decision on the appeal under 35 U.S.C. § 134 from the examiner's final rejection of claims 1-3, 5-8 and 10-13, which are all the claims pending in the application.

Claim 1 is illustrative of the subject matter on appeal and is reproduced below:

1. A method for treating proliferative skin diseases comprising the administration of an effective amount of tazarotene and an effective amount of a high-potency corticosteroid.

The references relied upon by the examiner are:

Yamamoto
Nagpal et al. (Nagpal)

5,236,906
5,650,279

Aug. 17, 1993
Jul. 22, 1997

GROUND OF REJECTION

Claims 1-3, 5-8 and 10-13 stand rejected under 35 U.S.C. § 103 as being unpatentable over Yamamoto and Nagpal.

We reverse.

PROCEDURAL BACKGROUND

This is the second time this application is before us on appeal. On September 24, 2003, a Decision was entered in the first appeal (Appeal No. 2002-1369) affirming a rejection of claims 1-3, 5-8 and 10-13 under 35 U.S.C. § 103 as being unpatentable over Yamamoto and Nagpal. Having concluded that the claims were upatentable over Yamamoto and Nagpal, the panel did not reach the only other ground of rejection in Appeal No. 2002-1369 - a rejection of claim 2 under 35 U.S.C. § 103 as being unpatentable over Smith¹ or Sequeira² in combination with Nagpal.³ For clarity, we reproduce representative claim 1, as it was presented in 2002-1369, below:

1. A method for treating proliferative skin diseases comprising the administration of an effective amount of tazarotene and an effective amount of a mid- or high-potency corticosteroid.

As set forth in the Decision, page 3, “the examiner found Yamamoto teaches that it is known in the art to use adrenocortical hormones which are

¹ Smith 5,874,074 Feb. 23, 1999

² Sequeira et al. (Sequeira) 4,775,529 Oct. 4, 1988

³ A rejection of claim 2 under 35 U.S.C. § 103 as being unpatentable over Smith or Sequeira in combination with Nagpal was not presented to us on this appeal. Accordingly, we interpret this to mean that the examiner has withdrawn the rejection. Paperless Accounting, Inc. v. Bay Area Rapid Transit Sys., 804 F.2d 659, 663, 231 USPQ 649, 651-652 (Fed. Cir. 1986), cert. denied, 480 U.S. 933 (1987).

among those utilized by appellant for treatment of skin diseases including psoriasis.” In addition, the prior Merits Panel noted (id.), “[t]he examiner further found that Nagpal discloses that it is known to use tazarotene for treatment of psoriasis.” According to the Decision (id.), the “examiner concludes that it would have been prima facie obvious to one of ordinary skill in the art to have used the combination of mid- or high-potency corticosteroid and tazarotene for the treatment of proliferative skin diseases as claimed in view of the combined teachings of Yamamoto and Nagpal.” Based on this evidence, the prior Merits Panel found (Decision, page 4), “the examiner has provided proper motivation for combining the [Yamamoto and Nagpal] references in accordance with the decision in Kerkhoven^[4].” Accordingly, the rejection of claims 1-3, 5-8 and 10-13 under 35 U.S.C. § 103 as being unpatentable over Yamamoto and Nagpal, was affirmed.⁵

In affirming the rejection, the Merits Panel reviewed appellant’s evidence of nonobviousness and made the following findings:

1. “Referring, first, to Example 1, the results of which are set forth in Figure 1, we note that the combination of tazarotene and a low-potency corticosteroid appear to provide better results than the combination of tazarotene and a mid-potency corticosteroid in reducing the severity of psoriasis in patients treated over a period of 12 weeks.” Decision, page 5, emphasis added.
2. “[I]t is impossible to conclude from Table II[, appellant’s specification, page 12,] that the incidence of adverse events was consistently lower

⁴ In re Kerkhoven, 626 F.2d 846, 205 USPQ 1069 (CCPA 1980).

⁵ We note, however, the prior Merit Panel’s statement (Decision, page 7), “as the examiner failed to comment on appellant’s evidence, we denominate our affirmance of the rejection as a new ground of rejection....”

in patients treated with mid- or high-potency corticosteroid in combination with tazarotene as compared with patients treated with low-potency corticosteroid in combination with tazarotene, or tazarotene alone. In particular, we note that patients suffered greater burning when treated with a combination of tazarotene and high-potency corticosteroid and a higher incidence of pruritus when treated with a combination of mid-potency corticosteroid and tazarotene." Decision, bridging paragraph, pages 5-6, emphasis added.

3. "Figure 2 shows treatment success in patients over a 12 week treatment period and four week post treatment period using the same four compositions. As with the results shown in Figure 1, it appears that the combination of low-potency corticosteroid and tazarotene provides better results than the combination of mid-potency corticosteroid and tazarotene." Decision, page 6, emphasis added.
4. "We do not find this Example [(Example 2)] persuasive in demonstrating unexpected results since the Example is unsupported by any data and is merely appellant's assertions that higher treatment success rates and decreased incidence of adverse events were provided when tazarotene was utilized in combination with mid- or high-potency corticosteroids." Decision, bridging paragraph, pages 6-7, emphasis added.

In response to the Decision, appellant elected to amend the claims and continue prosecution before the examiner. Specifically, appellant removed all references to "mid-potency corticosteroid" in the claims. Accordingly, the only corticosteroid encompassed by the claims before us on appeal is a "high-potency corticosteroid."

Against this backdrop, we now consider the merits of the rejection before us on appeal.

DISCUSSION

According to the examiner (Answer, page 3), the basis for the "rejection is set forth in a Board Decision mailed on September 24, 2003." We emphasize, however, that the scope of the claimed invention now before us on appeal is

different than the scope of the claimed invention in the previous appeal.

Accordingly, the prior Merits Panel's findings of fact Nos. 1 and 3, discussed above, are no longer relevant to the claims now on appeal. Specifically, these findings address appellant's evidence, presented in Example 1, Figure 1 and Figure 2, regarding a combination of tazarotene and a low-potency corticosteroid relative to the combination of tazarotene and a mid-potency corticosteroid. The claims now on appeal are limited to a high-potency corticosteroid. As the appellant's evidence demonstrates in Example 1, Figure 1 and Figure 2, a combination of tazarotene and a high potency corticosteroid was more efficacious than the other combinations tested. See also Brief, page 3.

Appellant does not argue the merits of the combination of Yamamoto with Nagpal. Instead, appellant asserts (Brief, page 3), "[a]pplicant believes the specification of the present application contains evidence of unexpected results which are sufficient to overcome the obviousness rejection for the scope of the claims as currently amended, notwithstanding any prima facie [sic] obviousness that [e]xaminer and the Board allege exists." We interpret this statement to mean that appellant has conceded that the examiner has met her burden of establishing a prima facie case of obviousness. Accordingly, we turn to appellant's evidence of unexpected results.

In this regard, appellant points out (Brief, bridging sentence, pages 3-4), "[a]ccording to the Board's observations [in Appeal No. 2002-1369], increasing the potency of the corticosteroid has no apparent advantage in combinations up to mid-potency corticosteroids, thus it is surprising that the combination of

tazarotene and a high-potency corticosteroid should have such a significant improvement over the other treatments.” More specifically, appellant asserts (Brief, page 4), Figure 1

shows a clinically significant reduction in plaque elevation for the tazarotene/high-potency corticosteroid combination compared to the other treatments. Thus, the combination of tazarotene and a high-potency corticosteroid represents a subset which has enhanced efficacy relative to the larger group represented by the combination of tazarotene and a corticosteroid, which enhanced efficacy would not be predicted based upon the properties of the remaining part of the larger group.

Stated differently, the evidence of record demonstrates an unexpected result for the combination of tazarotene and a high-potency corticosteroid. We agree.

The examiner, however, is unconvinced. As we understand the examiner’s assertion (Answer, page 5), the evidence of record does not provide a “true side-by-side comparison” of the reagents because different concentrations of corticosteroids were used. More specifically, in the Final Office Action⁶, the examiner points out (bridging paragraph, pages 2-3), “Example 1 and the Figures compare alternative topical application of 0.1% tazarotene gel and a placebo, 1% hydrocortisone acetate (low-potency corticosteroid), 0.05% alcometasone dipropionate (medium-potency corticosteroid) or 0.1% betamethasone valerate (high-potency corticosteroid).” According to the examiner (Final Office Action, page 3), “in order to argue unexpected and/or unobvious results, the amount of corticosteroid in each case has to be kept constant.”

⁶ Mailed December 3, 2003.

However, as appellant points out (Brief, page 5), since the potencies of the corticosteroids differ, a "comparison of a concentration of one compound to a concentration of a different compound is not proper." Rather, as we understand appellant's argument (Brief, page 6), the use of different concentrations of each corticosteroid effectively "normalizes" the cortocosteroids relative to their potency. According to appellant (id.),

The potency of the corticosteroid is assigned according to the particular formulation in which it is contained. Thus, the 1% hydrocortisone acetate formulation used in the patent specification is considered to be low-potency at a concentration of 1% in the vehicle it is administered. The same is true for 0.05% alcometasone dipropionate being a medium-potency corticosteroid and 0.1% betamethasone valerate being a high-potency corticosteroid.

According to appellant (id.), "[t]he whole point of assigning potency to a corticosteroid formulation is to indicate the activity of that formulation, and thus treatment for a particular condition is determined according to the assigned potencies of the various corticosteroid formulations." In support of this assertion appellant relies on Cornell⁷. The examiner, however, fails to address appellant's argument or the Cornell reference, maintaining instead (Answer, page 5),

[t]he examiner sees no reason why applicant could not utilize similar amounts of corticosteroids in each case. In addition, the utilization of low-, mid- and high-potency would imply that at identical concentrations, the efficacy of corticosteroids would be as recited and, thus, the skilled artisan would expect the high-potency corticosteroid to be most effective when used at similar concentration as the others.

⁷ Cornell et al. (Cornell), "Correlation of the Vasoconstriction Assay and Clinical Activity in Psoriasis," Arch Dermatol, Vol. 121, pp. 63-67 (1985).

The examiner, however, appears to miss the point. As the examiner recognizes the concentration of high-potency corticosteroid used in the experiments was 10-fold less than the concentration of low-potency corticosteroid. As appellant points out (Brief, page 6), the

[e]xaminer's position is inconsistent with itself in that [e]xaminer alleges "[t]he skilled artisan would have the reasonable expectation that the higher concentration of betamethasone valerate [(a high-potency corticosteroid)] would result in better improvement over treatment with lower concentrations of alcometasone dipropionate [a medium-potency corticosteroid]" but fails to recognize that the same reasoning would lead a skilled artisan to expect that the lower concentrations of alcometasone dipropionate [(a medium-potency corticosteroid)] and betamethasone valerate [(a high-potency corticosteroid)] relative to hydrocortisone acetate [(a low-potency corticosteroid)] would result in the treatment by the former two compounds being less effective. If the former two treatments are expected to be less effective, then the significant improvement of betamethasone valerate [(a high-potency corticosteroid)] over hydrocortisone acetate [(a low-potency corticosteroid)] that was observed must be unexpected.

Accordingly, we are not persuaded by the examiner's unsupported assertion regarding appellant's evidence.

Further, regarding the evidence presented in Table II of the specification, page 12, appellant asserts (Brief, page 4), "[a]ccording to Table II, the adverse events associated with the tazarotene/high-potency corticosteroid combination is at least as low or lower, than the other combinations with the exception of burning. Furthermore, the trend in the total number of adverse events points to a significant advantage for the tazarotene/high-potency corticosteroid combination." In support of this assertion, appellant provides the following table

(id.), which illustrates the downward trend in the total number of adverse events with increasing potency of the corticosteroid.

	Patients (%)			
	Taz/plac	Taz/low	Taz/med	Taz/high
Total Adverse Events	41	39	31	26

In view of the data tabulated in appellants table of "Total Adverse Events", we agree that the total number of adverse events is lower with the combination of Tazarotene with a high-potency corticosteroid than with tazarotene alone or with a low-potency corticosteroid.

As set forth in In re Hedges, 783 F.2d 1038, 1039, 228 USPQ 685, 686 (Fed. Cir. 1986):

If a prima facie case is made in the first instance, and if the applicant comes forward with reasonable rebuttal, whether buttressed by experiment, prior art references, or argument, the entire merits of the matter are to be reweighed. In re Piasecki, 745 F.2d 1468, 1472, 223 USPQ 785, 788 (Fed. Cir. 1984).


On reflection, having considered appellant's evidence and rebuttal arguments in the context of the claims now before us on appeal, we find that the evidence of record weighs in favor of non-obviousness. Accordingly, we reverse the rejection of claims 3, 5-8 and 10-13 under 35 U.S.C. § 103 as being unpatentable over Yamamoto and Nagpal.


OTHER ISSUES

We note that claim 11 appears to contain a typographical error with reference to the claim from which it depends. As it now reads, claim 11 depends from itself. Prior to any further action on the merits, we encourage the examiner and appellant to work together to resolve this issue.

REVERSED


William F. Smith
Administrative Patent Judge


Donald E. Adams
Administrative Patent Judge


Linda R. Poteate
Administrative Patent Judge

)
)
)
) BOARD OF PATENT
)
) APPEALS AND
) INTERFERENCES
)

Brent A Johnson
Allergan Inc T2-7H
2525 Dupont Drive
Irvine CA 92612